Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 10/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.49 |
| ▸ | ITGB2 | P05107 | 7/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 7/20 | 0.46 |
| ▸ | F2R | P25116 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4276933 | 1.00 | ITGAL (0.62) | ITGALNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13879613 | 0.88 | ITGAL (0.69) | ITGALSMN1; SMN2ITGB2ICAM1F2R | |
| SCHEMBL13879642 | 0.87 | ITGAL (0.54) | ITGALNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13879676 | 0.87 | ITGAL (0.65) | ITGALNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13879649 | 0.85 | ITGAL (0.85) | ITGALNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4288857 | 0.82 | ITGAL (0.51) | ITGALNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4288852 | 0.82 | ITGAL (0.51) | ITGALNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4276982 | 0.81 | ITGAL (0.53) | ITGALNPC1RAB9AITGB2ICAM1 | |
| SCHEMBL4276975 | 0.81 | ITGAL (0.53) | ITGALNPC1RAB9AITGB2ICAM1 | |
| SCHEMBL4290317 | 0.79 | RAB9A (0.56) | ITGALNPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | ITGAL 4495/4885NPC1 680/4885RAB9A 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.